{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:46:24Z","timestamp":1747226784924,"version":"3.40.5"},"reference-count":28,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>The angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are widely used for the treatment of hypertension (HT). Whether the use of these drugs increases the infectivity of novel coronavirus and results in an additional risk for morbidity and mortality of COVID-19 is a matter of interest.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Assess the effect of ACEI\/ARBs compared with other hypertensives on the clinical course and outcome in COVID-19 pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTINGS:<\/jats:title>\n            <jats:p>Tertiary care hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>We collected data on adult inpatients with COVID-19 pneumonia using ACEI\/ARBs versus other antihypertensives between 15 March 2020, and 15 February 2021.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>Severity, clinical course, mortality, and time to PCR negativity between patients using ACEI\/ARBs and other antihypertensives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>435<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              ACEI\/ARBs were used by 203 patients (46.6%) (median age: 71 [41\u201394] years), while 232 patients (53.4%) were using other antihypertensives (median age: 69 [22-93] years,\n              <jats:italic>P<\/jats:italic>\n              =.645 vs age of ACEI\/ARB users). There were no statistically significant differences between the ACEI\/ARBs users and non-users in the number of patients admitted to intensive care (65 cases [32%] vs. 74 cases [31.9%],\n              <jats:italic>P<\/jats:italic>\n              =.978), the median duration of stay in hospital (8 [1\u201354] days vs.7 [1\u201355] days,\n              <jats:italic>P<\/jats:italic>\n              =.806) the median duration of ICU stay (8 [1\u201340] days vs. 6 [1\u201325] days), and the mortality rate (48 cases [23.6%] vs. 61 [26.3%],\n              <jats:italic>P<\/jats:italic>\n              =.525). While the median days before transfer to the ICU was shorter in ACE\/ARBI non-users (2 [1\u201315] days vs. 3 [1\u201321] days,\n              <jats:italic>P<\/jats:italic>\n              =.02), the difference was not important clinically. The median time to PCR negativity was similar in ACEI\/ARBs users and non-users (13 [7\u201334] days for users and 13 [5\u201345] days for non-users), (\n              <jats:italic>P<\/jats:italic>\n              =.083).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>ACEI\/ARB use is probably unrelated to poor prognosis in COVID-19 pneumonia inpatients. ACEI\/ARBs did not prolong the time to PCR negativity. We conclude that using ACEI\/ARBs probably does not increase the infectivity of SARS-CoV-2.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Pharmacological therapies were not discussed in detail. The use of corticosteroids may affect the time to PCR negativity. We could not analyze the effect of obesity because of a lack of data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONFLICT OF INTEREST:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2021.268","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T12:31:11Z","timestamp":1636893071000},"page":"268-273","source":"Crossref","is-referenced-by-count":0,"title":["Patients with hypertension hospitalized with COVID-19 pneumonia using angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers or other antihypertensives: retrospective analysis of 435 patients"],"prefix":"10.5144","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-6508","authenticated-orcid":true,"given":"Seyma","family":"Baslilar","sequence":"first","affiliation":[{"name":"From the Department of Pulmonology, Umraniye Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengu","family":"Saylan","sequence":"additional","affiliation":[{"name":"From the Department of Pulmonology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"issue":"18","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan W-J","year":"2020","unstructured":"Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708\u20131720.","journal-title":"N Engl J Med."},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Zhou F Yu T Du R Fan G Liu Y Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan China: a retrospective cohort study. Lancet.  2020;395:1054\u20131062.","DOI":"10.1016\/S0140-6736(20)30566-3"},{"issue":"2","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271\u2013280.e8.","journal-title":"Cell"},{"issue":"8","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/jcmm.12573","article-title":"Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats","volume":"19","author":"Klimas J","year":"2015","unstructured":"Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015 Aug;19(8):1965\u201374.","journal-title":"J Cell Mol Med."},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai Y","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436: 112\u2013116.","journal-title":"Nature"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special Contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special Contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u20132200.","journal-title":"Eur Heart J"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt B","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u20131321.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"200463","DOI":"10.1148\/radiol.2020200463","article-title":"Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection","volume":"295","author":"Bernheim A","year":"2020","unstructured":"Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology. 2020;295(3):200463.","journal-title":"Radiology"},{"issue":"1","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1038\/s41598-021-84561-7","article-title":"Quantitative and semi-quantitative CT assessments of lung lesion burden in COVID-19 pneumonia","volume":"11","author":"Guan X","year":"2021","unstructured":"Guan X, Yao L, Tan Y, Shen Z, Sheng H, et al. Quantitative and semi-quantitative CT assessments of lung lesion burden in COVID-19 pneumonia. Sci Rep. 2021 Mar 4;11(1):5148.","journal-title":"Sci Rep"},{"issue":"1","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of Angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single center retrospective study","volume":"76","author":"Yang G","year":"2020","unstructured":"Yang G,Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of Angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A single center retrospective study. Hypertension. 2020 Jul;76(1):51\u201358.","journal-title":"Hypertension"},{"issue":"12","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang P","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J,et al. Association of inpatient use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020 Jun 5;126(12):1671\u20131681.","journal-title":"Circ Res."},{"issue":"1","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng J","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X,Ou M, Bi J. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757\u2013760.","journal-title":"Emerg Microbes Infect."},{"key":"e_1_3_1_14_2","first-page":"21","article-title":"Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19","volume":"24","author":"Senkal N","year":"2020","unstructured":"Senkal N, Meral R, Medetalibeyoglu A, Konyaoglu H, K\u00f6se M, T\u00fckek T. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Anatol J Cardiol. 2020; 24: 21\u20139.","journal-title":"Anatol J Cardiol."},{"issue":"12","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"e0244349","DOI":"10.1371\/journal.pone.0244349","article-title":"Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia","volume":"15","author":"Georges J-L","year":"2020","unstructured":"Georges J-L, Gilles FF, Cochet H, Bertrand A, De Tournemire M, Monguillon V, et al. Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia. PLoS One. 2020 Dec 21;15(12): e0244349.","journal-title":"PLoS One."},{"key":"e_1_3_1_16_2","first-page":"100627","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis","volume":"31","author":"Caldeira D","year":"2020","unstructured":"Caldeira D, Alvescde M, Gouveia R, Silv\u00e9rio MP, Cunha N, Ferreira AN, et al. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers and the risk of COVID-19 infection or severe disease: Systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2020 Dec;31: 100627.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"3","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1074248420976279","article-title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study","volume":"26","author":"Hakeam HA","year":"2021","unstructured":"Hakeam HA, Alsemari M, Al Duhailib Z, Ghonem L, Alharbi SA, Almutairy E,et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study. J Cardiovasc Pharmacol Ther. 2021 May;26(3):244\u2013252.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19; a systematic review and meta-analysis of 28,872 patients","volume":"22","author":"Baral R","year":"2020","unstructured":"Baral R,White M, Vassilou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19; a systematic review and meta-analysis of 28,872 patients. Curr Atheroscler Rep 2020; 22:61.","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (CO-VID-19): Do Angiotensin-converting enzyme inhibitors\/Angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein R","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Grani C. Coronavirus disease 2019 (CO-VID-19): Do Angiotensin-converting enzyme inhibitors\/Angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020 Apr 7;9(7): e016509.","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.120.046941","article-title":"COVID-19 and cardiovascular disease","volume":"141","author":"Clerkin KJ","year":"2020","unstructured":"Clerkin KJ, Fried JA, Raikhelkar J, Sayer Gabriel, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020 May 19;141(20):1648\u20131655.","journal-title":"Circulation"},{"issue":"7","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jmv.25785","article-title":"Organ \u2013 protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19","volume":"92","author":"Cheng H","year":"2020","unstructured":"Cheng H, Wang Y, Wang G-Q. Organ \u2013 protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020 Jul;92(7):726\u2013730.","journal-title":"J Med Virol"},{"issue":"19","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-Cov-2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster GM","year":"2020","unstructured":"Kuster GM, Pfister O,Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-Cov-2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020 May 14;41(19):1801\u20131803.","journal-title":"Eur Heart J"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"e57278","DOI":"10.7554\/eLife.57278","article-title":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","volume":"9","author":"Rossi PR","year":"2020","unstructured":"Rossi PR, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020 Apr 6;9: e57278.","journal-title":"Elife"},{"issue":"25","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-Angiotensin-Aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds HR","year":"2020","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB et al. Renin-Angiotensin-Aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441\u20132448.","journal-title":"N Engl J Med"},{"issue":"3","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu X","year":"2020","unstructured":"Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020 Mar;63(3):457\u2013460.","journal-title":"Sci China Life Sci"},{"issue":"6483","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp D","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 Mar 13;367(6483):1260\u20131263.","journal-title":"Science"},{"issue":"15","key":"e_1_3_1_27_2","first-page":"799","article-title":"Factors associated with prolonged viral RNA shedding in patients with COVID-19","volume":"71","author":"Xu K.","year":"2020","unstructured":"K. Xu, Y. Chen, J. Yuan, P. Yi, C. Ding, W. Wu, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020 Jul 28;71(15):799\u2013806.","journal-title":"Clin Infect Dis"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.amsu.2020.09.040","article-title":"Prolonged nucleic acid conversion and false-negative RT-PCR results in patients with COVID-19: A case series","volume":"59","author":"Trisnawati I","year":"2020","unstructured":"Trisnawati I, Riat El, Khair R,Puspitarani DA, Fauzi AR. Prolonged nucleic acid conversion and false-negative RT-PCR results in patients with COVID-19: A case series. Ann Med Surg (Lond). 2020 Nov; 59:224\u2013228.","journal-title":"Ann Med Surg (Lond)"},{"key":"e_1_3_1_29_2","first-page":"1","article-title":"Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis","volume":"19","author":"Budhathoki P","year":"2020","unstructured":"Budhathoki P, Shrestha DB, Rawal E, Khadka S. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis. SN Compr Clin Med. 2020 Oct 19:1\u201321.","journal-title":"SN Compr Clin Med"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T12:59:54Z","timestamp":1638363594000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2021.268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.5144\/0256-4947.2021.268"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2021.268","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"type":"print","value":"0256-4947"},{"type":"electronic","value":"0975-4466"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}